BIT's 8th Annual World Congress of Molecular & Cell Biology (CMCB-2018)
About CMCB-2018
BIT's 8th Annual World Congress of Molecular & Cell Biology (CMCB-2018) will be held during October 14-16, 2018 at Fukuoka, Japan.
CMCB-2018 is a dedicated event where you will have the opportunity to learn about new developments in the field of Molecular and Cell Biology, Life Sciences, Translational Medicine, and share aspects of your own work by submitting oral or poster presentations. With the participation of outstanding international experts, we hope productive discussions would stimulate new creative ideas to translate new discoveries into better practice and application. We hope your participation would contribute to your professional development and relationships. Wish you enjoy the conference.
We hope you will enjoy the conference and have an unforgettable memory in Fukuoka, Japan.
Keynote Speakers of CMCB-2018 

Dr. Tim Hunt
Emeritus Group Leader
Clare Hall Laboratories
Nobel Prize laureate in Physiology or Medicine, 2001
Dr. Behzad Mahdavi
VP Strategic Innovation & Alliances
Lonza Walkersville, Inc.
USA Dr. Reiko Kuroda
Tokyo University of Science

Dr. Kazuhide Inoue
Executive Vice President
Kyushu University
邓子新 Dr. Zixin Deng
Shanghai Jiao Tong University
Dr. William G. Rice
President and CEO
Aptose Biosciences Inc.

Sir Richard Timothy Hunt, FRS FMedSci FRSE (born 19 February 1943) is a British biochemist and molecular physiologist. He was awarded the 2001 Nobel Prize in Physiology or Medicine with Paul Nurse and Leland H. Hartwell for their discoveries of protein molecules that control the division of cells. In particular, Hunt discovered what he called cyclin: a protein in fertilised sea urchin eggs which cyclically aggregates and is depleted during cell division cycles. Following his PhD, Hunt returned to New York to work with London, in collaboration with Nechama Kosower, her husband Edward Kosower, and Ellie Ehrenfeld. While there, they discovered that tiny amounts of glutathione inhibited protein synthesis in reticulocytes and that tiny amounts of RNA killed the synthesis altogether. After returning to Cambridge, he again began work with Tony Hunter and Richard Jackson, who had discovered the RNA strand used to start haemoglobin synthesis. After 3–4 years, the team discovered at least two other chemicals acting as inhibitors.Hunt was elected a member of the European Molecular Biology Organization (EMBO) in 1978, serving as a member of the organisation's Fellowship Committee 1990–1993, its Meeting Committee 2008–2009, and its governing body, the Council, 2004–2009. He was elected a Fellow of the Royal Society (FRS) in 1991.

Behzad Mahdavi is serving as Vice President of Strategic Innovation & Alliances at Lonza, one of the world's leading suppliers to the Pharma&Biotech and Specialty Ingredient markets, as a Chairman of the Board of Exosomics, an innovator leader in the field of Liquid Biospy and as a member of Investment and Advisory committee for C3E Venture Capital Fund, one of the most active private fund in Canada. He began in his current position at Lonza in 2010 after three years serving as Head of Lonza Canada. Prior to joining Lonza, he was CEO of SAM Electron Technologies, a venture capital-backed company in the Life Sciences field, which was acquired in 2007 by a multinational company. During his entire career, Behzad worked for several private organizations, governmental companies and venture capital firms in different capacities as senior executive, advisor, CEO and board member. In these roles, he was involved in leading, managing and advising technological start-ups/companies in fund raising, strategic business development, efficient innovation management and commercialization/spinoff to create new profitable growth axis. He earned his MBA from the University of Quebec in Montreal, Canada, his Ph.D. in Chemistry from University of Sherbrooke, Canada, his M.S. in Industrial Chemicals & Environment from the University of Rennes, France and his B.Sc. in Chemical Engineering from ENSCR, France.

Dr. Reiko Kuroda, Professor at Research Institute for Science and Technology at Tokyo University of Science/ Professor Emeritus at The University of Tokyo, has obtained Ph.D. in Chemistry from The University of Tokyo. She worked at King’s College London in the Department of Chemistry and then Biophysics, as well as at Institute of Cancer Research, UK. Returned to Japan as an Associate Professor, and became a full professor in 1992, the first female full professor in the field of natural sciences at the University of Tokyo. She is a chemist as well as biologist and her main research interest is chiromorphology. In addition to her scientific activity, she is involved in science policy, higher education policy, science communication and promotion of STEM career especially for women/girls. L’Oreal UNESCO Women in Science Award (2013), Vice president of ICSU (International Council for Science, 2008-11), Scientific Advisory Board to the UN Secretary General (2013-16) etc.In Japan, member of Council of Science and Technology Policy (2001-7), and Ambassador of WINDS (Women’s Initiative in Developing STEM Career) (2016- ). She is a member of the Royal Swedish Academy of Sciences.

Professor Kazuhide Inoue is the Executive Vice-President of Kyushu University. ProfessorInoue has published over 200 papers on the subject of the function of purinergic receptors in CNS, especially in pain signaling. Inoue’s group has found that P2X4 receptors in spinal microglia has important role in the expression of neuropathic pain that is often refractory to treatment with NSAIDs and opioids, and the stimulation of P2Y6 receptors causes microglial phagocytosis.In 1975, he graduated School of Pharmaceutical Sciences, Kyushu University, and 1978 he started to research at National Institute of Health Sciences, Japan. After obtaining Ph.D from Kyusyu University in 1985, he studied abroad in NIH, USA, as a visiting fellow until 1987. He again studied abroad in University College London (Prof. G Burnstock), as an honorary research fellow from 1991 till 1992. In 2000, he became a professor of Graduate School of Pharmaceutical Sciences, Kyushu University. From 2014 till now, he works asthe Executive Vice-President of Kyushu University. He was awarded Science Technology Award from the Minister of Education, Culture, Sports, Science and Technology-Japan in 2007, the 3rd SetsuroEbashi Prize of The Japanese Pharmacological Society in 2010, Medal from His Majesty the Spanish Emperor as an honor of Royal Academy of Pharmacy in 2010, The Pharmaceutical Society of Japan Award in 2013, and Medal with Purple Ribbon from His Majesty the Emperor in 2014.

DENG Zixin, Professor of Microbiology and Chemical Biology at Wuhan University/Shanghai Jiaotong University,the current President of Chinese Society of Microbiology. He is a Member of Chinese Academy of Sciences, a Fellow of the World Academy of Sciences (formally the Third World Academy of Sciences, TWAS), and a Fellow of the American Academy of Microbiology. He was born in Hubei Province, China in 1957. He received his Bs degree on microbiology from Huazhong Agricultural University, Wuhan, China, in 1982, and a PhD degree on microbial genetics from the University of East Anglia, UK, in 1987, while working in Streptomyces group at John Innes Centre. Major interest is on Streptomyces genetics, biochemistry and molecular biology of antibiotic biosynthesis, and DNA backbone modification by sulfur (phosphorothiolation). He now acts as associate editor for ACS Chemical Biology, and as member of editorial boards for a number of journals including Cell Chemical Biology, Applied & Environmental Microbiology (ASM).
Expanding the Metabolic Power of the Mined NPs Pathways

Dr. William G. Rice serves as Chairman, President and CEO of Aptose Biosciences Inc., a publicly traded clinical stage biotechnology company developing first-in-class targeted agents to treat life-threatening hematological malignancies. Prior to Aptose, Dr. Rice served as Chairman, President, CEO of Cylene Pharmaceuticals, Inc. and led the development and sale of small molecule therapeuticsthat exploit kinase pathways and non-genotoxic mechanisms for activating p53 to kill cancer cells. Before Cylene, Dr. Rice was Founder, President, CEO and Director of Achillion Pharmaceuticals, Inc. Prior to that, he served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Centerand a Visiting Scientist to the IMCB of Singapore, and as a professorof Pediatric Hematology and Oncology at Emory University School of Medicine. Dr.Rice has held leadership roles in industry, government and academic sectors and accrued more than 30 years of executive, operational, business development, financial, product research, and product development skills.Over the course of his career, Dr. Rice identified multiple new molecular drug targets, delivered multiple first-in-class drugs to the clinic, and published peer-reviewed findings in Science, Nature, Cell, Nature Medicine, Proceedings of the National Academy of Sciences, among other prestigious journals. Dr. Rice holds a Ph.D. in Biochemistry from Emory University and was a postdoctoral trainee in the Department of Internal Medicine at the University of Michigan Medical Center.
Renowned Speakers of CMCB-2018 Dr. Reiko Kuroda
Tokyo University of Science
sp4 Dr. Marcel V CULCASI
Aix Marseille University
sp4 Dr. Sylvia Pietri
CNRS-Université de Provence
Bella Koifman Dr. Bella Koifman
Tel Aviv Sourasky Medical Center Israel
sp4 Dr. Yasuo Hitsumoto
Okayama University of Science
Karachi Dr. A. Hameed Khan
National Institutes of Health (NIH)
urszula_demkov Dr. Urszula Demkow
Warsaw Medical University
Poland Dr. Kentaro Doi
Osaka University
Dr. Ari Barzilai
Tel Aviv University
Dr. Martin Falk
Institute of Biophysics, the Czech Academy of Sciences
Czech Republic
Dr. Rahima Zennadi
Duke University Medical Center
Untitled-3_image030 Dr. Alena P. Sidenkova
Ural State Medical University
Russia Dr. Raimund Fromme
Arizona State University
2016012810352673499 Dr. Jinru Shia
Weill Cornell Medical College
Dr. Shi-Ming Tu
University of Texas MD Anderson Cancer Center
Dr. Martine Raes
University of Namur
Dr. Athina Zouni
Humboldt-Universität zu Berlin , Germany
Dr. Xiaoyan Jiang
University of British Colombia
Dr. Lixin Liu
University of Saskatchewan
Canada Dr. Lunawati Bennett
Union University College of PharmacyUSA Dr. Shimon Efrat
Tel Aviv University
rp00262 picture Dr. Andrew CK Law
Hospital Kuala Lumpur
tibbetts Dr. Stephen G. Tibbetts
California State University, San Bernardino
USA Dr. Guangbin Xia
University of New Mexico


Comments on Previous Event

It's been indeed a great pleasure for me to be a participant in the BIT's 7th CMCB, as it created a platform to be getting introduced and as well as to explore my research findings with the acclaimed scientific dignitaries. I too thank you for the great hospitality that gives me a pleasure of showing up for the future conferences. Keep up your good work and my comments on the conference arrangements and meetings would be an excellent and my score will be 9 out of 10 within which I would like to see more participants and speakers for this conference. Thank for your wishes and hopefully our journey as a team will continue for decades.

----- Senthil Kumar, India


Many Thanks for all the good work you've been doing for the Conference's success!

----- Arieh Zaritsky, Israel


I enjoyed the conference. It was a very precious opportunity for me to join this conference.

----- Mariko Miyachi, Japan


It was a wonderful conference indeed. I had a great time in the conference and in Xi'an in general.

----- Chia-Che Chang, Taiwan


I enjoyed the conference and really enjoyed finally meeting you in person. There were many positives about the meeting, especially the venue and the Hilton (I have Hilton Honors). The most I enjoy about the scientific venue of these meetings is the diversity of not only scientific subjects but the international participation and interaction. I always meet people from all over the world and learn new things.

----- Warren Ladiges, USA


I enjoyed the meeting very much. I would also like to report to you that the Session 402 that we were hosting went on very well. Thank you and you and other organizers for the wonderful meeting.

----- Xiaohe Yang, USA


The meeting in Xian was great and well attended, there were hundreds of people around. All was on time and well organized, the hotel great and the food fantastic. I am coming next year for sure.

----- Jaime Tisnado


Thanks for a great meeting. I will be happy to present at the 2018 meeting

----- Robert Plumb, UK


Thank you very much for sending me the Participants List. I really enjoyed very much the International Conference, which was held at Xi'an Hilton Hotel, owing to good hotel, nice foods, wonderful hospitality of the stuffs. I met several scientists and talked about many things with them, and also discussed on protein structure and so on during the conference. I am very appreciate to you for inviting me to the conference.Thank you very much again.

----- Kenji Ikehara, Japan


We came back to Moscow a week ago with great positive impression from Congress, Xi'an and China. Thank you

----- Alexander Krasnovsky, Japan

Previous Event Report
Exhibition and Sponsorship
As part of the CMCB-2018, an exhibition space will provide a unique opportunity for exhibitors to showcase their products and services to participants with interests in all areas of biotechnology. Developed to offer comfort to delegates while maximizing exhibitor exposure, the coffee breaks and poster sessions will all take place in the exhibition area promoting frequent and repeated opportunities for delegates to visit the exhibits.

Exhibitors' Advantages
• The exhibition will be visited by participants of the conference it means by your authentic target group from China and other countries.
• The exhibitors have the opportunity to present their exhibits more detailed, and have the opportunity for longer discussion with inquiring visitors – in most cases specialists – than during session discussions. More>>

Sponsorship Opportunity
CMCB-2018 is one of the most effective international marketing platforms in the field of life science and biomedicine, which offers a wide range of sponsoring categories for branding and highlighting your company in order to achieve the best publicity. More>>
Introduction to Fukuoka
Fukuoka is the capital city of Fukuoka Prefecture, situated on the northern shore of the Japanese island of Kyushu. It is the most populous city on the island, followed by Kitakyushu. It is the largest city and metropolitan area west of Keihanshin. The city was designated on April 1, 1972, by government ordinance. Greater Fukuoka, with 2.5 million people (2005 census), is part of the heavily industrialized Fukuoka–Kitakyushu zone as well as Northern Kyushu.As of 2015, Fukuoka is Japan’s fifth largest city, having passed the population of Kobe. As of July 2011, Fukuoka passed the population of Kyoto. Since the founding of Kyoto in 794, this marks the first time that a city west of the Kinki region has a larger population than Kyoto. In ancient times, however, the area near Fukuoka, the Chikushi region, was thought by some historians to have possibly been even more influential than the Yamato region.

News Released

Tentative Scientific Program Released
Keynote Speakers Released 
Academicians Forum Speakers Released 
Hotel Released 
Speaking proposals are now being accepted, download the Format of Abstract and CV
Call for Exhibitors and Sponsors
Call for Collaborative Partners, Media and Journals

Hosting Organization
Official Travel Agency
BIT’s Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2017-2018 BIT Congress Inc.